| Literature DB >> 34475993 |
Zixuan Zhou1,2, Zuyi Ma2,3, Zhenchong Li1,2, Hongkai Zhuang2,3, Chunsheng Liu2,3, Yuanfeng Gong2, Shanzhou Huang1,2,4, Chuanzhao Zhang1,2,4, Baohua Hou1,2,4.
Abstract
Background: Recent evidence has shown that CKLF-like MARVEL transmembrane domain containing 3 (CMTM3) promoted carcinogenesis and tumor progression in a variety of cancer types. The goal of our study is to investigate the association between CMTM3 and pancreatic cancer (PC). Materials andEntities:
Keywords: CMTM3; cancer aggressiveness; pancreatic cancer; prognosis
Year: 2021 PMID: 34475993 PMCID: PMC8408105 DOI: 10.7150/jca.57082
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Correlation between CMTM3 and clinicopathological features in pancreatic cancer
| Characteristics | CMTM3 expression | |||||
|---|---|---|---|---|---|---|
| TCGA cohort | GPPH cohort | |||||
| High (n=83) | Low (n=83) | P value | High (n=46) | Low (n=46) | P value | |
|
| 0.6324 | 0.8169 | ||||
| <60 | 34 | 30 | 12 | 14 | ||
| ≥60 | 49 | 53 | 34 | 32 | ||
|
| 0.7556 | 0.5312 | ||||
| Male | 43 | 46 | 22 | 26 | ||
| Female | 40 | 37 | 24 | 20 | ||
|
| 0.4717 | 0.2023 | ||||
| I | 7 | 12 | 12 | 6 | ||
| II | 71 | 66 | 31 | 34 | ||
| III | 1 | 2 | 2 | 4 | ||
| IV | 3 | 1 | 0 | 2 | ||
| Unkonwn | 1 | 2 | 1 | 0 | ||
|
|
|
| ||||
| G1 | 8 | 21 | 3 | 5 | ||
| G2 | 50 | 45 | 28 | 39 | ||
| G3 | 24 | 14 | 12 | 2 | ||
| G4 | 1 | 1 | 0 | 0 | ||
| Unkonwn | 0 | 2 | 3 | 0 | ||
|
| 0.4611 | 0.09651 | ||||
| <4 | 49 | 53 | 8 | 16 | ||
| ≥4 | 29 | 23 | 38 | 30 | ||
| Unkonwn | 5 | 7 | 0 | 0 | ||
|
| 0.1605 | 0.7093 | ||||
| Yes | 63 | 54 | 16 | 14 | ||
| No | 18 | 27 | 28 | 32 | ||
| Unkonwn | 2 | 2 | 2 | 0 | ||
|
| 0.07104 |
| ||||
| Head of Pancreas | 70 | 58 | 26 | 16 | ||
| Body/Tail of Pancreas | 9 | 18 | 18 | 29 | ||
| Unkonwn | 4 | 7 | 2 | 1 | ||
|
|
|
| ||||
| Yes | 28 | 15 | 18 | 6 | ||
| No | 46 | 60 | 28 | 40 | ||
| Unkonwn | 9 | 8 | 0 | 0 | ||
|
| 0.1551 | 0.7664 | ||||
| Yes | 21 | 13 | 15 | 13 | ||
| No | 50 | 59 | 30 | 33 | ||
| Unkonwn | 12 | 11 | 1 | 0 | ||
|
| 0.6226 | 0.169 | ||||
| Yes | 47 | 46 | 25 | 18 | ||
| No | 28 | 34 | 19 | 27 | ||
| Unkonwn | 8 | 3 | 2 | 1 | ||
Figure 3Kaplan-Meier analyses for overall survival (OS) and disease-free survival (DFS) were performed between the high and low CMTM3 expression groups with a median cut-off. (A-B) The high expression group was associated with poorer OS (p=0.031) and DFS (p=0.0047) in the TCGA cohort. (C-D) The high expression group was associated with poorer OS (p=8.636e-04) and DFS (p=6.425e-04) in the GPPH cohort. (E) Multivariate cox regression analysis showed CMTM3 overexpression was the independent prognostic indicator for OS and DFS in patients with PC.
Univariate and multivariate Cox regression analysis of risk factors associated with overall survival
| Clinicopathological variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | |
| CMTM3 expression (High vs. Low) | 6.02 | 4.39-7.65 |
| 4.09 | 3.02-5.16 |
|
| Gender (Male vs. Female) | 1.72 | 0.68-2.76 | 0.32 | |||
| Age (≥50 vs. <50) | 1.27 | 0.51-2.03 | 0.59 | |||
| Tumor site (Head vs. Body/Tail) | 1.31 | 0.91-1.71 | 0.09 | |||
| Tumor size (≥4 cm vs. <4 cm) | 1.53 | 1.17-1.89 |
| 1.64 | 0.50-2.78 | 0.41 |
| Lymphnodes positive (Yes vs. No) | 3.21 | 1.98-4.44 |
| 2.66 | 1.27-4.06 |
|
| AJCC stage (Advanced vs. Early) | 3.47 | 2.16-4.78 |
| 3.20 | 2.38-4.02 |
|
| Histologic grade (High vs. Low) | 2.12 | 1.20-3.04 |
| 1.89 | 1.12-2.66 |
|
Univariate and multivariate Cox regression analysis of risk factors associated with disease-free survival
| Clinicopathological variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | |
| CMTM3 expression (High vs. Low) | 5.61 | 3.91-7.01 |
| 3.24 | 1.92-4.56 |
|
| Gender (Male vs. Female) | 1.31 | 0.43-2.19 | 0.72 | |||
| Age (≥50 vs. <50) | 1.42 | 0.78-2.06 | 0.31 | |||
| Tumor site (Head vs. Body/Tail) | 1.56 | 0.89-2.23 | 0.13 | |||
| Tumor size (≥4 cm vs. <4 cm) | 1.89 | 1.21-2.57 |
| 2.00 | 0.68-3.32 | 0.68 |
| Lymphnodes positive (Yes vs. No) | 2.96 | 1.86-4.06 |
| 2.47 | 1.26-3.68 |
|
| AJCC stage (Advanced vs. Early) | 3.21 | 2.09-4.33 |
| 2.72 | 2.09-3.35 |
|
| Histologic grade (High vs. Low) | 2.03 | 1.17-2.89 |
| 1.47 | 0.47-2.47 | 0.35 |